Review Article: Efficacy and safety of rabeprazole in treating gastroesophageal reflux disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue SUPPL. 3, 2004, Pages

  Lim, P W Y ^a   Goh, K L ^b  

^a Eisai Asia Regional Services Pte Ltd   (Singapore)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

CYP4502C19 genetic polymorphism; Gastroesophageal reflux disease; On demand; Second generation PPI

Indexed keywords

ACETYLSALICYLIC ACID; CARBAMAZEPINE; CISAPRIDE; CITALOPRAM; CLARITHROMYCIN; CLOMIPRAMINE; CYTOCHROME P450; DIAZEPAM; DIGOXIN; ESOMEPRAZOLE; FUROSEMIDE; IMIPRAMINE; KETOCONAZOLE; LANSOPRAZOLE; NORDAZEPAM; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PANTOPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; THEOPHYLLINE; WARFARIN;

CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; PRIORITY JOURNAL; SIDE EFFECT;

EID: 4544376539     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03592.x     Document Type: Conference Paper

References (43)

1. Holtmann G. Reflux disease: the disorder of the third millennium. Eur. J. Gastroenterol. Hepatol. 2001; 13: S5-S11.
2. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD) - Acid reflux and symptom patterns. Aliment Pharmacol. Ther. 2003; 17: 537-45.
3. Goh KL, Chang CS, Fock KM, Ke M, Park HJ, Lam SK. Gastro-oesophageal reflux disease in Asia. J. Gastroenterol. Hepatol. 2000; 15: 230-8.
4. Rabeprazole US Package Insert. [Cited 6 July 2004.] Available from URL:http://www.aciphex.com/aciphexpi. pdf
5. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol. Ther. 1998; 12: 1079-89.
6. Warrington S, K.Baisley, Boyce B, Tejura A, Morocutti N, Miller. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol. Ther. 2002; 16: 1301-7.
7. Baisley K, Warrington S, Tejura B, Morocutti A, Miller N. Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers. J. Gastroenterol. Hepatol. 2002; 17: A845.
8. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59-67.
9. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51.
10. Pipkin GA, Mills JG. Onset of action of antisecretory drugs: beneficial effects of a rapid increase in intragastric pH in acid reflux disease. Scand. J. Gastroenterol. (Suppl.) 1999; 230: 3-8.
11. Pantoflickova D, G.Dorta, Ravic P, Jornod AL, Blum. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol. Ther. 2003; 17: 1507-14.
12. Luo JY, Chun YN, Wang XQ, Zhu YL, Jun Kong. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J. Gastroenterol. 2003; 9: 2583-6.
13. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 1992; 22: 1-21.
14. Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P450. J. Pharmacokinet. Biopharm. 1996; 24: 461-73.
15. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999; 9: 539-49.
16. Yamada S, Onda M, Kato S et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J. Gastroenterol. 2001; 36: 669-72.
17. Ishizaki T, Y.Horai. Cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol. Ther. 1999; 13 (Suppl. 3): 27-36.
18. Andersson T, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole the S-isomer of omeprazole. Aliment Pharmacol. Ther. 2001; 15: 1563-9.
19. Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur. J. Gastroenterol. Hepatol. 2001; 13: S43-7.
20. Tytgat GN. Shortcomings of the first-generation proton pump inhibitors. Eur. J. Gastroenterol. Hepatol. 2001; 13: S29-33.
21. Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol. Ther. 2002; 16: 1811-7.
22. Furuta T, Shirai N, Watanabe F et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin. Pharmacol. Ther. 2002; 72: 453-60.
23. Kawamura M, Ohara S, Koike T et al. The effects of lansoprazole on erosive reflux esophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol. Ther. 2003; 17: 965-73.
24. Kita T, Sakaeda T, Aoyama N et al. Optimal dose of omeprazole for CYP2C19 extensive metabolisers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. Biol. Pharm. Bull. 2002; 25: 923-7.
25. McColl KE, Kennerley P. Proton pump inhibitors - differences emerge in hepatic metabolism. Dig. Liver Dis. 2002; 34: 461-7.
26. Ariizumi K, Ohara S, Koike T Sr et al. The Therapeutic effects of rabeprazole at a dose of 10mg on reflux esophagitis may not be influenced by CYP2C19 polymorphism. Gastroenterology 2004; 126 (Suppl. 2): 340 (Abstract).
27. Howden CW, Castell DO, Cohen S, Freston JW, Orlando RC, Robinson M. The rationale for continuous maintenance treatment of reflux esophagitis. Arch. Intern. Med. 1995; 155: 1465-71.
28. Humphries TJ, Merritt GJ. Drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol. Ther. 1999; 13 (Suppl. 3): 18-26.
29. Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J. Clin. Gastroenterol. 1990; 12: S54-63.
30. Kromer W. Similarities and differences in the properties of substituted benzimidazoles. a comparison between pantoprazole and related compounds. Digestion 1995; 56: 443-54.
31. Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin. Pharmacokinet. 1996; 31: 386-406.
32. Humphries TJ. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Dig. Dis. Sci. 1991; 36: 1665-9.
33. Ishizaki T, Chiba K, Manabe K et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin. Pharmacol. Ther. 1995; 58: 155-64.
34. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet. 2001; 40: 523-37.
35. Horn J. The proton-pump inhibitors: similarities and differences. Clin. Ther. 2000; 22: 266-80.
36. Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-esophageal reflux disease. Aliment Pharmacol. Ther. 2002; 16: 479-85.
37. Robinson M, Fitzgerald S, Hegedus R., Murthy A, Jokubaitis L, FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol. Ther. 2002; 16: 445-54.
38. Thjodleifsson B, Rindi G, Fiocca R et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-esophageal reflux disease over 5 years. Aliment Pharmacol. Ther. 2003; 17: 343-51.
39. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am. J. Gastroenterol. 2002; 97: 1332-9.
40. Bytzer P. On-demand therapy for gastro-oesophageal reflux disease. Enr J. Gastroenterol. Hepatol. 2001; 13: S19-22.
41. Bytzer P, Blum AL, de Herdt D. Glostrup, Denmark; Lausanne, Switzerland; Beerse, Belgium. On-demand rabeprazole therapy provides heartburn control in long-term management of nonerosive reflux disease. Gastroenterology 2003; 124: A227.
42. Bytzer P, Blum AL, de Herdt D. Glostrup, Denmark; Lausanne, Switzerland; Beerse, Belgium. Fast and complete control of heartburn in on-demand rabeprazole (RAB) maintenance therapy in patients with nonerosive reflux disease (NERD). Gastroenterology 2003; 124: A228.
43. Talley NJ, Venables TL, Green JR et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease. a placebo-controlled trial of on-demand therapy for 6 months. Eur J. Gastroenterol. Hepatol. 2002; 14: 857-63.